Close
Solutions
Online Inquiry

CONTACT US

USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

scFv Generation from Hybridoma Cells

As a super provider of diverse antibodies, Creative Biolabs offers customers several approaches for scFv generation such as one-stop solution for developing CAR from Hybridoma, which is a very mature and useful technology for scFv construction.

scFv generation from Hybridoma cells

From vce.bioninja.com.au.

As we known, a variable region (Fv) always consists of a heavy chain variable region (VH) and a light chain variable region (VL), while a single-chain variable fragment (scFv) normally consists of a VH and a VL connected together via a peptide linker. Our seasoned scientists can generate a scFv from Hybridoma Cell Lines following this procedure: firstly, we immunize mice with the antigen, and then remove the spleen to get splenocytes (B cells). After the splenocytes and myeloma cells fusion step, hydridoma cell lines will be established for producing specific monoclonal antibodies. Our skilled scientists from Creative Biolabs can convert the Fv from full monoclonal antibody into a scFv, which can target the tumor antigen our customer interested in. Finally, we will clone this scFv, together with other CAR components into a Lentivirus vector for the future steps.

Creative Biolabs is a world leading expert in antibody engineering field, which can provide our clients with the best-class service in order to meet their research needs. Our years of experience guarantee we can offer you our high quality scFv generation.

All services and products are only for lab research use, not for any clinical diagnosis or treatment.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.